The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Friday, August 14, 2026

Subject of the day

QIA.DE

Concerning the House

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Netherlands · www.qiagen.com

The Ledger
LineMar 2025Jun 2025Sep 2025Dec 2025
Revenue$483.46M$533.54M$532.58M$540.42M
Gross profit$308.68M$334.29M$331.26M$325.27M
Operating income$125.16M$135.97M$137.29M$121.88M
Net income$90.76M$96.25M$130.04M$107.83M
Diluted EPS0.430.460.630.52
Free cash flow$95.48M$120.60M$114.57M$116.55M
CapEx-$44.26M-$40.84M-$50.45M-$71.58M
Quotation

$37.04

-0.03 (-0.1%)

52w hi$45.95
52w lo$27.83
Vol493.09K
As ofAug 13
The Verdict

Hold

Our score +0.08

Short-0.09
Medium+0.19
Long+0.20

computed 2026-08-13

By the Numbers

Qiagen N.V.

Healthcare · Diagnostics & Research

Market cap$7.78B
Enterprise value$8.51B
Trailing P/E22.15x
Forward P/E16.82x
EV / EBITDA11.59x
P / S (ttm)3.70x
Profit margin19.5%
Return on equity11.9%
Revenue growth+0.3%
Earnings growth+13.6%
Debt / equity49.25
Risk Metrics
Beta vs SPX0.13
Corr SPX0.08
Annual vol27.1%
Annual ret-5.5%
Sharpe-0.20
Max DD-42.5%

Window: 504 trading days (489 obs)

Layer Breakdown
LayerRawContribution
Fundamental+0.20
Sector+0.12
Technical+0.00
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-08-13

Recent Sessions
DateOpenHighLowCloseVol
Aug 13$37.49$37.95$37.35493.09K
Aug 12$36.81$37.04$36.44$37.04868.85K
Aug 11$38.15$38.21$37.08$37.08723.08K
Aug 10$36.91$38.45$36.90$38.45752.81K
Aug 7$37.00$37.40$36.30$36.46664.42K